Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
John M Burke, Kristina S Yu, Uche Mordi, Brian Bloudek, Nicholas Liu, Tycel Phillips
BACKGROUND: The ECHELON-2 5-year update showed continued clinically meaningful improvements in progression-free survival (PFS) and overall survival with frontline (1L) A+CHP (brentuximab vedotin in combination with cyclophosphamide, doxorubicin, prednisone) vs CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in CD30-expressing peripheral T-cell lymphomas (PTCLs). OBJECTIVE: To estimate PTCL annual prevalence in the United States in 2031 without and with A+CHP using data from the ECHELON-2 5-year update...
March 2023: Journal of Managed Care & Specialty Pharmacy
#22
JOURNAL ARTICLE
Kok Haw Jonathan Lim, Panagiotis Ntellas, Daniel Anderson, Lilly Simpson, Michael Braun, Marios Adamou, Jorge Barriuso, Katerina Dadouli, Jacqueline Connell, Joseph Williams, Theodora Germetaki, Deirdre Lehwald, Niall Fitzpatrick, Mark Cutting, Danielle McCool, Jurjees Hasan, Saifee Mullamitha, Kalena Marti, Mark Saunders, Konstantinos Kamposioras
The COVID-19 pandemic has resulted in unprecedented changes to the lives of patients with cancer. To evaluate the impact of the COVID-19 pandemic on the mental health and well-being of patients with colorectal cancer, we conducted a prospective longitudinal questionnaire study at a UK tertiary cancer centre. In total, 216 participants were included: mean age 65 years, 57% ( n = 122) male, 92% ( n = 198) of white ethnicity. Amongst participants who completed the screening psychometric questionnaire, 24% ( n = 48/203) reported anxiety (GAD-7 ≥ 5), 15% ( n = 31/204) depressive symptoms (PHQ-9 ≥ 10), 3% ( n = 5/190) probable post-traumatic stress disorder (PC-PTSD-5 ≥ 4), and 31% ( n = 66/213) poor well-being (WHO-5 < 50)...
February 15, 2023: Cancers
#23
JOURNAL ARTICLE
Raya Saab, Victor Santana, Anas Obeid, Meenakshi Devidas, Asim Belgaumi, Nickhill Bhakta, Paula Naidu, Vaskar Saha, Iyad Sultan, Ramandeep Singh Arora, Lilly Mukoka, Sima Jeha
PURPOSE: Formal training in clinical research methodologies is limited in limited-resource countries. Through collaboration among high- and middle-resource settings and in response to an identified need verbalized by regional pediatric oncology practitioners, Pediatric Oncology East & Mediterranean Group and St Jude Global developed a workshop focused on capacity building in research skills. Here, we describe its structure, implementation, and early results. METHODS: Leveraging virtual capabilities, the format included lectures and small group breakout exercise sessions, for 3 hours per day on 2 consecutive days per week for 2 consecutive weeks...
February 2023: JCO global oncology
#24
JOURNAL ARTICLE
Joseph Kauer, Lilli Sophie Sester, Katharina Kriegsmann, Niels Weinhold, Michael Ober, Carsten Müller-Tidow, Hartmut Goldschmidt, Marc-Steffen Raab, Sandra Sauer
Patients with relapsed refractory multiple myeloma (RRMM) that are triple-exposed to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies have a poor prognosis. Standard treatment for these patients has not been established. Patients with extramedullary disease or secondary plasma cell leukaemia often display high tumour cell proliferation and might therefore be susceptible to chemotherapy. While current regimens are often platinum-based, we present single-centre data on 70 patients with RRMM who were treated with cyclophosphamide, etoposide, and dexamethasone (CED) after a median of four lines of therapy...
January 21, 2023: Hematological Oncology
#25
RANDOMIZED CONTROLLED TRIAL
Stephen R D Johnston, Masakazu Toi, Joyce O'Shaughnessy, Priya Rastogi, Mario Campone, Patrick Neven, Chiun-Sheng Huang, Jens Huober, Georgina Garnica Jaliffe, Irfan Cicin, Sara M Tolaney, Matthew P Goetz, Hope S Rugo, Elzbieta Senkus, Laura Testa, Lucia Del Mastro, Chikako Shimizu, Ran Wei, Ashwin Shahir, Maria Munoz, Belen San Antonio, Valérie André, Nadia Harbeck, Miguel Martin
BACKGROUND: Adjuvant abemaciclib plus endocrine therapy previously showed a significant improvement in invasive disease-free survival and distant relapse-free survival in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2; also known as ERBB2)-negative, node-positive, high-risk, early breast cancer. Here, we report updated results from an interim analysis to assess overall survival as well as invasive disease-free survival and distant relapse-free survival with additional follow-up...
January 2023: Lancet Oncology
#26
JOURNAL ARTICLE
Jena V Lilly, Jo Lynne Rokita, Jennifer L Mason, Tatiana Patton, Stephanie Stefankiewiz, David Higgins, Gerri Trooskin, Carina A Larouci, Kamnaa Arya, Elizabeth Appert, Allison P Heath, Yuankun Zhu, Miguel A Brown, Bo Zhang, Bailey K Farrow, Shannon Robins, Allison M Morgan, Thinh Q Nguyen, Elizabeth Frenkel, Kaitlin Lehmann, Emily Drake, Catherine Sullivan, Alexa Plisiewicz, Noel Coleman, Luke Patterson, Mateusz Koptyra, Zeinab Helili, Nicholas Van Kuren, Nathan Young, Meen Chul Kim, Christopher Friedman, Alex Lubneuski, Christopher Blackden, Marti Williams, Valerie Baubet, Lamiya Tauhid, Jamie Galanaugh, Katie Boucher, Heba Ijaz, Kristina A Cole, Namrata Choudhari, Mariarita Santi, Robert W Moulder, Jonathan Waller, Whitney Rife, Sharon J Diskin, Marion Mateos, Donald W Parsons, Ian F Pollack, Stewart Goldman, Sarah Leary, Chiara Caporalini, Anna Maria Buccoliero, Mirko Scagnet, David Haussler, Derek Hanson, Ron Firestein, Jason Cain, Joanna J Phillips, Nalin Gupta, Sabine Mueller, Gerald Grant, Michelle Monje-Deisseroth, Sonia Partap, Jeffrey P Greenfield, Rintaro Hashizume, Amy Smith, Shida Zhu, James M Johnston, Jason R Fangusaro, Matthew Miller, Matthew D Wood, Sharon Gardner, Claire L Carter, Laura M Prolo, Jared Pisapia, Katherine Pehlivan, Andrea Franson, Toba Niazi, Josh Rubin, Mohamed Abdelbaki, David S Ziegler, Holly B Lindsay, Ana Guerreiro Stucklin, Nicolas Gerber, Olena M Vaske, Carolyn Quinsey, Brian R Rood, Javad Nazarian, Eric Raabe, Eric M Jackson, Stacie Stapleton, Robert M Lober, David E Kram, Carl Koschmann, Phillip B Storm, Rishi R Lulla, Michael Prados, Adam C Resnick, Angela J Waanders
Pediatric brain tumors are the leading cause of cancer-related death in children in the United States and contribute a disproportionate number of potential years of life lost compared to adult cancers. Moreover, survivors frequently suffer long-term side effects, including secondary cancers. The Children's Brain Tumor Network (CBTN) is a multi-institutional international clinical research consortium created to advance therapeutic development through the collection and rapid distribution of biospecimens and data via open-science research platforms for real-time access and use by the global research community...
November 3, 2022: Neoplasia: An International Journal for Oncology Research
#27
JOURNAL ARTICLE
Yelena P Wu, Jada G Hamilton, Kimberly A Kaphingst, Jakob D Jensen, Wendy Kohlmann, Bridget G Parsons, Helen M Lillie, Xuechen Wang, Benjamin Haaland, Ali P Wankier, Douglas Grossman, Jennifer L Hay
Skin cancer has become increasingly common among young adults; however, this population does not consistently adhere to recommended methods for preventing the disease. Interventions in college settings have relied on appearance-focused appeals and have not been able to examine the cumulative effect of multiple behavior change and skin cancer risk communication strategies. The goal of the current study was to examine the unique and combined impacts of personalized ultraviolet (UV) radiation photographs, genetic testing for skin cancer risk, and general skin cancer prevention education...
October 28, 2022: Journal of Cancer Education: the Official Journal of the American Association for Cancer Education
#28
JOURNAL ARTICLE
Jiejie Xie, Xueyan Wu, Jianmei Wu, Fang Huang, Luning Xu
Lung cancer is the leading cause of death from malignant tumors in China, and non-small cell lung cancer (NSCLC) accounts for >80% of all types of lung cancer. Novel immunotherapeutic agents targeting programmed death protein-1 (PD-1) and its ligands [programmed death ligands (PD-L)1 and 2] have emerged as important therapeutic measures and trends in the treatment of advanced NSCLC. Sintilimab (trade name, Daboshu) is a humanized IgG4 monoclonal antibody targeting PD-1 that was developed by Innovent Biologics and Eli Lilly and Company...
December 2022: Oncology Letters
#29
JOURNAL ARTICLE
Fantine Giap, Lillie O'steen, I-Chia Liu, Lisa E Spiguel, Christiana M Shaw, Christopher G Morris, Raymond B Mailhot Vega, Judith L Lightsey, Julie A Bradley, Nancy P Mendenhall, Paul G Okunieff, Natalie A Lockney
Background: To assess outcomes and toxicity after low-energy intraoperative radiotherapy (IORT) for early-stage breast cancer (ESBC). Materials and methods: We reviewed patients with unilateral ESBC treated with breast-conserving surgery and 50-kV IORT at our institution. Patients were prescribed 20 Gy to the surface of the spherical applicator, fitted to the surgical cavity during surgery. Patients who did not meet institutional guidelines for IORT alone on final pathology were recommended adjuvant treatment, including additional surgery and/or external-beam radiation therapy (EBRT)...
2022: Reports of Practical Oncology and Radiotherapy
#30
JOURNAL ARTICLE
Umang Swami, Raquel Mae Zimmerman, Roberto H Nussenzveig, Edgar Javier Hernandez, Yeonjung Jo, Nicolas Sayegh, Sergiusz Wesolowski, Lesli A Kiedrowski, Pedro C Barata, Gordon Howard Lemmon, Mehmet A Bilen, Elisabeth I Heath, Lakshminarayan Nandagopal, Hani M Babiker, Sumanta K Pal, Michael Lilly, Benjamin L Maughan, Benjamin Haaland, Mark Yandell, Oliver Sartor, Neeraj Agarwal
BRCA1 -mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to BRCA2 -mutated prostate cancer. The reason for this differential response is not clear. We hypothesized this differential sensitivity to PARP inhibitors may be explained by distinct genomic landscapes of BRCA1 versus BRCA2 co-segregating genes. In a large dataset of 7,707 men with advanced prostate cancer undergoing comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA), 614 men harbored BRCA1 and/or BRCA2 alterations...
2022: Frontiers in Oncology
#31
JOURNAL ARTICLE
Jacob Hall, Samuel Rubinstein, Amy Lilly, Jeffrey M Blumberg, Bhishamjit Chera
PURPOSE: Localized amyloidosis is a condition characterized by deposits of fibrillary proteins confined to a single organ. The most common subtype is amyloid light chain amyloidosis, which is caused by secretion of amyloidogenic light chain by a monoclonal population of plasma cells. We present a review and discussion of the literature in the context of a case presentation of localized amyloid light chain amyloidosis of the nasopharynx treated with radiation alone. METHODS AND MATERIALS: We reviewed literature relevant to this topic from 1970 to the present...
September 7, 2022: Practical Radiation Oncology
#32
Sabine Kürzel, André-René Blaudszun, Lilly Stahl, Regina Herbst, Frank Kroschinsky, Josef Birkmann, Annette Hänel, Kerstin Schaefer-Eckart, Gerhard Ehninger, Friedrich Fiedler, Martin Bornhäuser, Stephan Fricke, Mathias Hänel
No abstract text is available yet for this article.
September 9, 2022: Journal of Cancer Research and Clinical Oncology
#33
REVIEW
Robert M Nelson, Laurie S Conklin, Wendy J Komocsar, Fei Chen, Forrest Williamson, Wallace V Crandall
Master protocols are innovative clinical trial designs that enable new approaches to analytics and operations, creating value for patients and drug developers. To date, the use of master protocols in pediatric drug development has been limited, focused primarily on pediatric oncology with limited experience in rare and ultra-rare pediatric diseases. This article explores the application of master protocols to pediatric programs required by FDA and EMA based on adult developmental programs. These required programs involve multiple assets developed in limited pediatric populations for registrational purposes...
September 1, 2022: Therapeutic Innovation & Regulatory Science
#34
RANDOMIZED CONTROLLED TRIAL
Virginie Westeel, Pascal Foucher, Arnaud Scherpereel, Jean Domas, Philippe Girard, Jean Trédaniel, Marie Wislez, Patrick Dumont, Elisabeth Quoix, Olivier Raffy, Denis Braun, Marc Derollez, François Goupil, Jacques Hermann, Etienne Devin, Hubert Barbieux, Eric Pichon, Didier Debieuvre, Gervais Ozenne, Jean-François Muir, Stéphanie Dehette, Jérôme Virally, Michel Grivaux, François Lebargy, Pierre-Jean Souquet, Faraj Al Freijat, Nicolas Girard, Emmanuel Courau, Reza Azarian, Michel Farny, Jean-Paul Duhamel, Alexandra Langlais, Franck Morin, Bernard Milleron, Gérard Zalcman, Fabrice Barlesi
BACKGROUND: Even after resection of early-stage non-small-cell lung cancer (NSCLC), patients have a high risk of developing recurrence and second primary lung cancer. We aimed to assess efficacy of a follow-up approach including clinic visits, chest x-rays, chest CT scans, and fibre-optic bronchoscopy versus clinical visits and chest x-rays after surgery for resectable NSCLC. METHODS: In this multicentre, open-label, randomised, phase 3 trial (IFCT-0302), patients aged 18 years or older and after complete resection of pathological stage I-IIIA NSCLC according to the sixth edition of the TNM classification were enrolled within 8 weeks of resection from 122 hospitals and tertiary centres in France...
September 2022: Lancet Oncology
#35
JOURNAL ARTICLE
Tomoko Yamazaki, Andrew J Gunderson, Miranda Gilchrist, Mark Whiteford, Maria X Kiely, Amanda Hayman, David O'Brien, Rehan Ahmad, Jeffrey V Manchio, Nathaniel Fox, Kayla McCarty, Michaela Phillips, Evelyn Brosnan, Gina Vaccaro, Rui Li, Miklos Simon, Eric Bernstein, Mary McCormick, Lena Yamasaki, Yaping Wu, Ashley Drokin, Trevor Carnahan, Yy To, William L Redmond, Brian Lee, Jeannie Louie, Eric Hansen, Matthew C Solhjem, Julie Cramer, Walter J Urba, Michael J Gough, Marka R Crittenden, Kristina H Young
BACKGROUND: TGF-β is an immunosuppressive cytokine that is upregulated in colorectal cancer. TGF-β blockade improved response to chemoradiotherapy in preclinical models of colorectal adenocarcinoma. We aimed to test the hypothesis that adding the TGF-β type I receptor kinase inhibitor galunisertib to neoadjuvant chemoradiotherapy would improve pathological complete response rates in patients with locally advanced rectal cancer. METHODS: This was an investigator-initiated, single-arm, phase 2 study done in two medical centres in Portland (OR, USA)...
September 2022: Lancet Oncology
#36
JOURNAL ARTICLE
Iain Simpson
This industry update covers the period from January 1 through January 31, 2022, and is based on information sourced from company press releases, scientific literature, patents and news websites. January 2022 saw Janssen and Midatech expand their collaboration on bioresorbable polymer microsphere technology for drug delivery. Takeda announced its plans to acquire UK-based Adaptate Biotherapeutics and Gandeeva raised further investment funds to support its drug discovery and development platform focused on the evaluation of protein-drug interactions...
August 4, 2022: Therapeutic Delivery
#37
JOURNAL ARTICLE
Jason J Z Liao, Feng Zhou, Heng Zhou, Lilli Petruzzelli, Kevin Hou, Ekaterine Asatiani
Identifying the maximum tolerated dose (MTD) and recommending a phase II dose for an investigational treatment is crucial in cancer drug development. A suboptimal dose often leads to a failed late-stage trial, while an overly toxic dose causes harm to patients. There is a very rich literature on trial designs for dose-finding oncology clinical trials. We propose a novel hybrid design that maximizes the merits and minimizes the limitations of the existing designs. Building on 2 existing dose-finding designs: a model-assisted design (the modified toxicity probability interval) and a dose-toxicity model-based design, a hybrid design of the modified toxicity probability interval design and a dose-toxicity model such as the logistic regression model is proposed, incorporating optimal properties from these existing approaches...
July 8, 2022: International Journal of Cancer. Journal International du Cancer
#38
JOURNAL ARTICLE
Nour Khalil, Eddy Lilly, Marwan Alkassis, Raymond Mansour, Georges Abi Tayeh, Julien Sarkis, Fouad Aoun
No abstract text is available yet for this article.
June 2022: Indian Journal of Surgical Oncology
#39
JOURNAL ARTICLE
Victoria Rose, Lilli Cooper, Georgios Pafitanis, Katy Hogben, Anup Sharma, Asmat H Din
BACKGROUND: Breast reconstructive standards are increasingly high oncologically, aesthetically, and practically. Autologous breast reconstruction remains the gold standard which, buried, after nipple-sparing mastectomy (where oncologically safe) or wise pattern reduction for large or ptotic patients, with contralateral symmetrisation where required, enables single-stage reconstruction. However, previous series report prohibitively high revision rates. This series prospectively compares a series of buried and non-buried free flaps for breast reconstruction...
April 25, 2022: Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS
#40
JOURNAL ARTICLE
T Ivanics, L Rajendran, P A Abreu, M P A W Claasen, C Shwaartz, M S Patel, W J Choi, A Doyle, H Muaddi, I D McGilvray, M Selzner, R Beecroft, J Kachura, M Bhat, N Selzner, A Ghanekar, M Cattral, B Sayed, T Reichman, L Lilly, G Sapisochin
Background: Curative-intent therapies for hepatocellular carcinoma (HCC) include radiofrequency ablation (RFA), liver resection (LR), and liver transplantation (LT). Controversy exists in treatment selection for early-stage tumours. We sought to evaluate the oncologic outcomes of patients who received either RFA, LR, or LT as first-line treatment for solitary HCC ≤ 3 cm in an intention-to-treat analysis. Materials and methods: All patients with solitary HCC ≤ 3 cm who underwent RFA, LR, or were listed for LT between Feb-2000 and Nov-2018 were analyzed...
May 2022: Annals of Medicine and Surgery
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
